We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: influenza vaccine
MedXY News
EnglishTag

influenza vaccine

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evaluating the Safety of Same-Day COVID-19 and Influenza Vaccination: Insights from a Large Veterans Affairs Target Trial Emulation
Infectious DiseasesCOVID-19 vaccineinfluenza vaccine

Evaluating the Safety of Same-Day COVID-19 and Influenza Vaccination: Insights from a Large Veterans Affairs Target Trial Emulation

By MedXY|Jul 2, 2026

A large U.S. Veterans Affairs study found no increased 90-day risk of adverse events after same-day COVID-19 and influenza vaccination compared to influenza vaccination alone, supporting the safety of coadministration with updated COVID-19

Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial
Clinical UpdatesDiabetes Mellitus
geriatrics

Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial

By MedXY|Mar 28, 2026

This secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines provide superior protection against cardiorespiratory and cardiovascular hospitalizations in older adults with diabetes, particularly those with a

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status
Diabetes & EndocrinologyDiabetes Mellitusgeriatric medicine

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

By MedXY|Jan 25, 2026

A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patien

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial
Cardiologycardiovascular outcomeschronic kidney disease

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

By MedXY|Dec 25, 2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective o

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Infectious Diseasesimmunobridginginfluenza vaccine

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study

By MedXY|Nov 23, 2025

A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited react

Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation
Clinical Updatesinfluenza vaccineolder adults

Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation

By MedXY|Nov 23, 2025

This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the c

High‑Dose Influenza Vaccine Reduces Hospitalisations in Older Adults
Infectious Diseasesinfluenza vaccineolder adults

High‑Dose Influenza Vaccine Reduces Hospitalisations in Older Adults

By MedXY|Nov 11, 2025

A prespecified pooled analysis of two large randomised pragmatic trials (DANFLU-2 and GALFLU) found high‑dose influenza vaccine reduced hospitalisation for influenza or pneumonia by 8.8% versus standard‑dose in adults ≥65 years, with larger

Updated Evidence for Covid-19, RSV, and Influenza Vaccines in the 2025-2026 Season: A Comprehensive Review
Infectious DiseasesCOVID-19 vaccineinfluenza vaccine

Updated Evidence for Covid-19, RSV, and Influenza Vaccines in the 2025-2026 Season: A Comprehensive Review

By MedXY|Oct 31, 2025

A systematic review supports the continued safety and effectiveness of Covid-19, RSV, and influenza vaccines for the upcoming 2025-2026 season, highlighting detailed vaccine efficacy, safety profiles, and recommendations for at-risk populat

Evaluating the Incremental Benefit of Two Versus One Dose of Influenza Vaccine in Influenza-Naive Children Under Nine: A Systematic Review and Meta-Analysis
Infectious Diseasesinfluenza vaccinePediatrics

Evaluating the Incremental Benefit of Two Versus One Dose of Influenza Vaccine in Influenza-Naive Children Under Nine: A Systematic Review and Meta-Analysis

By MedXY|Oct 4, 2025

This systematic review and meta-analysis assess the additional protection from a second dose of influenza vaccine in vaccine-naive children under nine years old, highlighting significant benefits particularly for those under three years.

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence
Cardiologycardiovascular outcomesinfluenza vaccine

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

By MedXY|Oct 9, 2025

This review synthesizes evidence on high-dose versus standard-dose influenza vaccines for cardiovascular outcomes in older adults, focusing on the large DANFLU-2 trial and complementary studies, highlighting modest cardiovascular benefits a

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial
Clinical Updatescardiovascular outcomesinfluenza vaccine

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

By MedXY|Oct 6, 2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and

Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial
Cardiologycardiovascular diseaseheart failure

Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial

By MedXY|Oct 6, 2025

The DANFLU-2 trial reveals that high-dose influenza vaccine significantly reduces hospitalization for influenza and cardiovascular events in older adults, including those with heart failure, compared to the standard-dose vaccine.

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients
Cardiologyclinical trialheart failure

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

By MedXY|Oct 6, 2025

The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.

High-Dose Influenza Vaccines Cut Hospitalizations: Landmark Trials Shape Cardiovascular Prevention
Cardiologycardiovascular preventionhigh-dose vaccine

High-Dose Influenza Vaccines Cut Hospitalizations: Landmark Trials Shape Cardiovascular Prevention

By MedXY|Dec 18, 2025

Two massive randomized trials show high-dose flu vaccines reduce influenza-related and cardiorespiratory hospitalizations in older adults, reinforcing vaccination as a vital cardiovascular prevention strategy.

Comparing the Effectiveness of Influenza Vaccines: Subunit Vaccine vs. Split-Virion Vaccine
Family Medicine & Nutritioninfluenza vaccinevaccine effectiveness

Comparing the Effectiveness of Influenza Vaccines: Subunit Vaccine vs. Split-Virion Vaccine

By MedXY|Oct 1, 2025

A prospective study shows split-virion vaccines offer significantly higher protection against influenza than subunit vaccines in adults 50 and older, highlighting the importance of vaccine selection.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities